SEC Company Response from Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE) — Aug 8, 2019

Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: Aug. 8, 2019 · CIK: 0001444192 · Accession: 0001171843-19-005356

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-233063

Date

August 8, 2019

Author

Not clearly detected

Form

CORRESP

Company

Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)

Letter

Re: Acasti Pharma Inc.

August 8, 2019

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Registration Statement on Form F-3

File No. 333-233063

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acasti Pharma Inc., a Québec corporation (the “Company”), respectfully requests that the Securities and Exchange Commission (the “Commission) accelerate the effective date of the above-referenced Registration Statement (the “Registration Statement”) so that the same will become effective at 4:00 p.m. on August 9, 2019 or as soon thereafter as is practicable.

The Company also requests the Commission confirm the effective date and time of the Registration Statement to Company counsel, Osler, Hoskin & Harcourt LLP, Attention: Jason Comerford, by email to JComerford@osler.com.

ACASTI PHARMA INC.

By: /s/ Janelle D’Alvise

Name: Janelle D’Alvise

Title: Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

        August 8, 2019

        VIA EDGAR

        Securities and Exchange Commission

        Division of Corporation Finance

        100 F. Street, N.E.

        Washington, D.C. 20549

        Re: Acasti Pharma Inc.

        Registration Statement on Form F-3

        File No. 333-233063

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended,
Acasti Pharma Inc., a Québec corporation (the “Company”), respectfully requests that the Securities and Exchange
Commission (the “Commission) accelerate the effective date of the above-referenced Registration Statement (the “Registration
Statement”) so that the same will become effective at 4:00 p.m. on August 9, 2019 or as soon thereafter as is practicable.

The Company also requests the Commission confirm the effective date and time of the Registration Statement to Company counsel,
Osler, Hoskin & Harcourt LLP, Attention: Jason Comerford, by email to JComerford@osler.com.

    ACASTI PHARMA INC.

    By:
    /s/ Janelle D’Alvise

    Name: Janelle D’Alvise

    Title: Chief Executive Officer

SecProbe.io